<DOC>
	<DOCNO>NCT00053638</DOCNO>
	<brief_summary>This 48-week study evaluate safety efficacy new tablet formulation contain two FDA-approved drug HIV-infected patient receive prior therapy . This tablet take one two FDA-approved drug once-daily regimen . Study physicians evaluate subject determine certain medical condition , laboratory test value , medication use , drug allergy would exclude study .</brief_summary>
	<brief_title>A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion criterion : Participants must able provide inform consent . Have document HIV1 infection . Have receive 14 day prior treatment antiretroviral drug . Meet laboratory test criterion . Women childbearing potential must abstain sexual intercourse use acceptable contraception . Must able take study medication direct complete study visit evaluation 48 week study . Exclusion criterion : Enrolled HIV treatment study . Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>HIV-1 Efavirenz Tenofovir</keyword>
</DOC>